Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study.

@article{Rigatos2003PaclitaxelAL,
  title={Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study.},
  author={Sotiris K. Rigatos and Dimitrios Tsavdaridis and Athanasios Athanasiadis and John G. Stathopoulos and George P. Stathopoulos},
  journal={Oncology reports},
  year={2003},
  volume={10 6},
  pages={1817-9}
}
Due to the cumulative cardiotoxicity of doxorubicin in cancer treatment, the tendency of the physician to find a substitute has led to the use of liposomal encapsulated doxorubicin, as well as other similar compounds. Doxorubicin and paclitaxel, two of the most active agents for breast cancer, have often been used in combination for this condition. In the present study we combined liposomal doxorubicin with paclitaxel with the intention of diminishing the toxicity of the cardiac muscle. Twenty… CONTINUE READING